10 Best Performing Mid Cap Stocks to Buy According to Analysts

4. BridgeBio Pharma Inc. (NASDAQ:BBIO)

Year-to-Date Performance as of February 24: 29.90%

Upside Potential as of February 24: 37.88%

Number of Hedge Fund Holders: 48

BridgeBio Pharma Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company that develops transformative medicines for genetic diseases and cancers. It has a diverse pipeline of clinical-stage programs, which include AG10 for TTR amyloidosis, low-dose infigratinib for achondroplasia, and gene therapies like BBP-631 for congenital adrenal hyperplasia.

On February 22, Scotiabank increased its price target for BridgeBio Pharma Inc. (NASDAQ:BBIO) to $52 from $49, reaffirming an Outperform rating. The analysts were impressed with how well the company’s new drug, Attruby, is selling for a heart condition called transthyretin amyloid cardiomyopath. The drug’s rapid adoption signals a strong preference for it as a first-line treatment.

Since its FDA approval in late 2024, Attruby has seen rapid uptake, with 1,028 prescriptions written by 516 providers by mid-February 2025. This strong initial demand translated to $2.9 million in net product revenue in Q4, contributing to a total yearly revenue of $221.9 million. The drug’s European approval as BEYONTTRA further supports its potential. Attruby’s success comes from proven clinical efficacy. As the first near-complete TTR stabilizer, it demonstrated reductions in cardiovascular death and hospitalizations in clinical trials.

BridgeBio Pharma Inc. (NASDAQ:BBIO) anticipates further growth through additional regulatory approvals, notably in Japan, which will generate further milestone payments and revenue. The company is actively investing in commercialization. This is reflected in increased selling, general, and administrative expenses, to ensure that Attruby reaches a wider patient base.